Sangamo BioSciences Inc
Most Recent
Sangamo Therapeutics Rises on Positive Clinical Trial Results
On Friday last week, Sangamo Therapeutics (SGMO) and Pfizer (PFE) announced promising updated results from their Phase 1/2 ALTA trial.
Comparing Sangamo’s and Amarin’s Revenue Growth
Sangamo is conducting Phase 1/2 studies on SB-318 and SB-913 for treating MPS (mucopolysaccharidosis) I and MPS II inherited metabolic disorders, respectively.
Analysts’ Recommendations for Sangamo Therapeutics and Amarin
On April 5, Sangamo Therapeutics (SGMO) closed at $12.58, 3.62% above its previous closing price, 100.96% above its 52-week low of $6.26, and 38.78% below its 52-week high of $20.55.
How Are Sangamo Therapeutics’ Earnings and Expenses Trending?
In the first nine months of 2018, Sangamo Therapeutics (SGMO) reported net income of -$49.7 million compared to -$41.5 million in the same period the prior year.
A Financial Overview of Sangamo Therapeutics in December 2018
In the first nine months of 2018, Sangamo Therapeutics’ (SGMO) net revenues grew ~145% to reach $57.6 million from $23.5 million.
Taking Stock of Sangamo’s Financial Performance
In this series, we explore Sangamo’s financials, analysts’ views on the stock, and the company’s valuation metrics.
CRISPR Therapeutics: Analysts’ View in November
On November 9, CRISPR Therapeutics’ (CRSP) stock price closed at $36.37, which is an ~3.53% decline from its close of $37.70 on November 8.
Audentes Therapeutics’ Promising Product Pipeline
In this series, we’ll take a look at six stocks with a focus on gene therapy that have promising products in their pipelines.
Sangamo Therapeutics: The Promise of Zinc Fingers
For fiscal 2018 and fiscal 2019, Sangamo is expected to generate revenues of $82.73 million and $89.39 million, respectively.
A Financial Overview of Intellia Therapeutics in September
In the second quarter, Intellia Therapeutics (NTLA) reported collaboration revenue of $7.7 million.
How CRISPR Therapeutics Is Positioned in September
CRISPR Therapeutics (CRSP) reported net collaboration revenues of $1.1 million in the second quarter of 2018 compared to $3.6 million in the second quarter of 2017.
Bluebird Bio’s Valuation on September 6
Bluebird Bio (BLUE) reported a net loss of $2.91 per share on revenues of $7.8 million in Q2 2018, a 53% decline year-over-year.
Why Sangamo Therapeutics Stock Is Down More than 22% Today
Today, Sangamo Therapeutics (SGMO) stock is down over 22% in afternoon trading. Yesterday, SGMO stock closed at $19.05.
Sangamo Therapeutics Rose despite Q2 Sales Miss, Higher Losses
Sangamo Therapeutics (SGMO) stock rose ~16% in afternoon trading. SGMO released its Q2 earnings results on August 8 after the market closed.
CRISPR Stock Has Seen Soild Growth in the Last 12 Months
CRISPR Therapeutics has risen 24% between May 11 and May 17.
Exploring Collaboration between Pfizer and Sangamo Therapeutics
On January 3, Pfizer and Sangamo Therapeutics announced a collaboration for developing a potential gene therapy for the treatment of ALS.
Pfizer and Sangamo Therapeutics: Hemophilia A Gene Therapy
In May 2017, Sangamo Therapeutics (SGMO) and Pfizer (PFE) announced a collaboration for hemophilia A gene therapy, which includes SB-525.
Pfizer on the Street: Analyst Recommendations in February 2018
In January 2017, Pfizer (PFE) and Sangamo Therapeutics (SGMO) entered into a key collaboration agreement.
What Investors Should Know about Pfizer’s Recent Developments
The recent developments for Pfizer (PFE) include various product developments, pipeline developments, and commercial developments.
Analysts’ Recommendations for Bioverativ in January 2018
Fourteen analysts were tracking Bioverativ in January 2018. Four analysts recommended “strong buys,” while two recommended “buys” on the stock.
The Evolution of Hemophilia Treatment—And What It Means for BioMarin
BioMarin’s BMN 270 is a gene therapy being investigated for hemophilia A. On April 20, it announced early data of the phase-1 and phase-2 study of BMN 270.
Could Gene Therapy Be a Next-Generation Treatment for Hemophilia?
Gene therapy is the emerging platform for hemophilia care. If approved, it would be a paradigm.
How Could Baxalta Acquisition Become a Catalyst for Shire?
Shire’s (SHPG) acquisition of Baxalta could prove to be a catalyst for Shire’s valuation in the near term. The combined entity is expected to record revenues of $20 billion by fiscal 2020.
BLUE Is IBB’s Worst-Performing Small-Cap on Disappointing Data
On December 7, 2015, bluebird bio (BLUE) fell 37.6%. The stock fell after it announced disappointing clinical data for its BB305 treatment.